Post

New research · Allergy & Immunology
Allergy · 4d
Cohort studyAllergy · 2026

Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double-Blind Randomised Placebo-Controlled Trial.

Lara Šošić, Stephan C Flory, Claudia C V Lang … Pål Johansen
Read paper
Allergy & ImmunologyCohort study

Intralymphatic immunotherapy reduced symptoms and medication use by 50% in 2023.

Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double-Blind Randomised Placebo-Controlled Trial.

Lara Šošić … Pål Johansen
Allergy · 2026
Background

Intralymphatic immunotherapy (intralymphatic immunotherapy) has been investigated for two decades in small clinical trials, typically using native allergens adsorbed to aluminium hydroxide (alum).

Methods

Sixty adults with grass pollen-induced allergic rhinoconjunctivitis (allergic rhinoconjunctivitis) were randomised to receive intralymphatic immunotherapy with grass allergoid (equivalent to 60 ng Phl p 5; n = 31) or placebo (n = 29).

n = 31
Results

patients had fewer symptoms and used less medication in 2023

2022 cSMS reduction
33%
2023 cSMS reduction
50%
More results

Intralymphatic immunotherapy was well tolerated, with no severe adverse events (severe adverse events).

In the placebo group, one mild and no moderate reactions occurred.

No allergen-specific systemic reactions were observed.

Rhinitis Quality of Life Questionnaire improved with relative reductions of 22% and 13% (p > 0.05), respectively.

“
Conclusion · 1 of 2

Intralymphatic immunotherapy with a grass pollen allergoid formulated with microcrystalline tyrosine was well tolerated and associated with clinically relevant reductions in symptom and medication use in grass pollen-induced allergic rhinoconjunctivitis.

Conclusion · 2 of 2

In this small study cohort, intralymphatic immunotherapy proved to be efficient and safe, but further optimisation of dosing regimens should follow.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
r = 0.78
Higher scores on the new measure meant children reported a higher overall impact
Meta-analysis
-1.87
H1 antihistamines likely resulted in a small reduction in eczema severity
Case-control
0.191
median level of miRNA-21 in adults with asthma, found to be higher
Cohort Study
1.4%
the low percentage of infants who experienced a slow heart rate
Cohort Study
27%
high blood pressure in the lungs was confirmed in patients with severe lung scarring
AI / Informatics
1 in 6 adults
of adults get their health information from artificial intelligence
Study
93.6%
children under age 3 whose blood allergy test came back negative despite symptoms
Cohort Study
OR 0.16
far fewer allergic skin reactions when the antiseptic was thoroughly washed off first